131 related articles for article (PubMed ID: 29861869)
1. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy.
Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Varey E; Khammari A; Dréno B; Denis MG
Oncotarget; 2018 May; 9(38):25265-25276. PubMed ID: 29861869
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study.
Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Varey E; Khammari A; Dréno B; Denis MG
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920470
[TBL] [Abstract][Full Text] [Related]
3. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond
Marsavela G; Johansson PA; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Khattak MA; Meniawy TM; Amanuel B; Millward M; Hayward NK; Ziman MR; Gray ES; Calapre L
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339135
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.
Cabel L; Riva F; Servois V; Livartowski A; Daniel C; Rampanou A; Lantz O; Romano E; Milder M; Buecher B; Piperno-Neumann S; Bernard V; Baulande S; Bieche I; Pierga JY; Proudhon C; Bidard FC
Ann Oncol; 2017 Aug; 28(8):1996-2001. PubMed ID: 28459943
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression.
Warburton L; Calapre L; Pereira MR; Reid A; Robinson C; Amanuel B; Ziman M; Millward M; Gray E
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33238616
[TBL] [Abstract][Full Text] [Related]
8. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
Bidard FC; Madic J; Mariani P; Piperno-Neumann S; Rampanou A; Servois V; Cassoux N; Desjardins L; Milder M; Vaucher I; Pierga JY; Lebofsky R; Stern MH; Lantz O
Int J Cancer; 2014 Mar; 134(5):1207-13. PubMed ID: 23934701
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
Jacobsoone-Ulrich A; Jamme P; Alkeraye S; Dzwiniel V; Faure E; Templier C; Mortier L
Melanoma Res; 2016 Apr; 26(2):153-6. PubMed ID: 26636908
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
Lipson EJ; Velculescu VE; Pritchard TS; Sausen M; Pardoll DM; Topalian SL; Diaz LA
J Immunother Cancer; 2014; 2(1):42. PubMed ID: 25516806
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
12. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract][Full Text] [Related]
13. Direct circulating tumor DNA detection from unpurified plasma using a digital PCR platform.
Sefrioui D; Beaussire L; Perdrix A; Clatot F; Michel P; Frebourg T; Di Fiore F; Sarafan-Vasseur N
Clin Biochem; 2017 Nov; 50(16-17):963-966. PubMed ID: 28645720
[TBL] [Abstract][Full Text] [Related]
14. Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.
Busser B; Lupo J; Sancey L; Mouret S; Faure P; Plumas J; Chaperot L; Leccia MT; Coll JL; Hurbin A; Hainaut P; Charles J
Biomed Res Int; 2017; 2017():5986129. PubMed ID: 28484715
[TBL] [Abstract][Full Text] [Related]
15. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
[TBL] [Abstract][Full Text] [Related]
17. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.
Amato CM; Hintzsche JD; Wells K; Applegate A; Gorden NT; Vorwald VM; Tobin RP; Nassar K; Shellman YG; Kim J; Medina TM; Rioth M; Lewis KD; McCarter MD; Gonzalez R; Tan AC; Robinson WA
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708981
[TBL] [Abstract][Full Text] [Related]
18. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma.
Madic J; Piperno-Neumann S; Servois V; Rampanou A; Milder M; Trouiller B; Gentien D; Saada S; Assayag F; Thuleau A; Nemati F; Decaudin D; Bidard FC; Desjardins L; Mariani P; Lantz O; Stern MH
Clin Cancer Res; 2012 Jul; 18(14):3934-41. PubMed ID: 22645051
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline.
Knol AC; Vallée A; Herbreteau G; Nguyen JM; Varey E; Gaultier A; Théoleyre S; Saint-Jean M; Peuvrel L; Brocard A; Quéreux G; Khammari A; Denis MG; Dréno B
Exp Dermatol; 2016 Oct; 25(10):783-8. PubMed ID: 27194447
[TBL] [Abstract][Full Text] [Related]
20. Heparinase enables reliable quantification of circulating tumor DNA from heparinized plasma samples by droplet digital PCR.
Sefrioui D; Beaussire L; Clatot F; Delacour J; Perdrix A; Frebourg T; Michel P; Di Fiore F; Sarafan-Vasseur N
Clin Chim Acta; 2017 Sep; 472():75-79. PubMed ID: 28729136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]